BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21958851)

  • 1. Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.
    Martiniova L; Cleary S; Lai EW; Kiesewetter DO; Seidel J; Dawson LF; Phillips JK; Thomasson D; Chen X; Eisenhofer G; Powers JF; Kvetnansky R; Pacak K
    Nucl Med Biol; 2012 Feb; 39(2):215-26. PubMed ID: 21958851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal model of metastatic pheochromocytoma: evaluation by MRI and PET.
    Martiniova L; Lai EW; Thomasson D; Kiesewetter DO; Seidel J; Merino MJ; Kvetnansky R; Pacak K
    Endocr Regul; 2009 Apr; 43(2):59-64. PubMed ID: 19856710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
    Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
    J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
    Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
    Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
    Kaji P; Carrasquillo JA; Linehan WM; Chen CC; Eisenhofer G; Pinto PA; Lai EW; Pacak K
    Eur J Endocrinol; 2007 Apr; 156(4):483-7. PubMed ID: 17389464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
    Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?
    Hentschel M; Rottenburger C; Boedeker CC; Neumann HP; Brink I
    Clin Nucl Med; 2012 Feb; 37(2):e24-9. PubMed ID: 22228360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular monoamine transporters expression in pheochromocytomas and paragangliomas according to scintigraphy and positron emission tomography behavior.
    Bacca A; Pucci A; Lorenzini D; Chiacchio S; Volterrani D; Ferrari M; Sellari Franceschini S; Materazzi G; Basolo F; Bernini G
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):396-401. PubMed ID: 35133098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):484-93. PubMed ID: 19862519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
    Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K
    Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.
    Hadi M; Chen CC; Whatley M; Pacak K; Carrasquillo JA
    J Nucl Med; 2007 Jul; 48(7):1077-83. PubMed ID: 17574980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications.
    Manso J; Bertazza L; Barollo S; Mondin A; Censi S; Carducci S; Ferrara AM; Boschin IM; Zovato S; Schiavi F; Gregianin M; Pennelli G; Iacobone M; Mian C
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.